Trial Profile
Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Jul 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Durvalumab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ACTS 30
- 06 Jun 2023 Results of phase 1b trial (n=30) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 31 Jan 2021 Planned number of patients changed from 39 to 30.
- 31 Jan 2021 Interim Results (n=14; data cut off date: 25 Feb, 2020) of the safety and feasibility of the combination of neoadjuvant chemoradiotherapy with durvalumab (PD-L1 inhibitor) in potentially resectable stage III Non-small cell lung cancer, presented at the 2020 World Conference on Lung Cancer.